NCT03178942已完成3 期
A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream, 5% (Encube Ethicals) Compared to Elimite™ Cream (Permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 254
- 试验地点
- 14
- 主要终点
- Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies
研究概览
简要总结
Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5%in the Treatment of Scabies.
详细描述
A Randomized, Double-Blind, Parallel-Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Permethrin Cream 5% (Encube Ethicals) Compared to Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in the Treatment of Scabies.
The objectives of this study are to:
- Evaluate the therapeutic equivalence of the Test formulation, Permethrin Cream, 5% (Encube Ethicals) to the marketed product, Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.) in patients with scabies.
- Compare the safety of Test and Reference treatments in patients with scabies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
盲法说明
The study product will be randomized, packaged and blinded so that the packaging for both treatments look identical.
入排标准
- 年龄范围
- 2 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or non-pregnant, non-lactating female, 2 years of age or older.
- •If female and of childbearing potential, prepared to abstain from sexual intercourse or use a reliable method of contraception during the study (e.g., double barrier methods, intrauterine device (IUD), oral, transdermal or injected hormonal contraceptives). Female patients using hormonal contraceptives should have been on the same product/dosing regimen for at least 28 days before baseline and should not change this regimen during the study.
- •Signed informed consent that meets all criteria of current FDA and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) regulations. For patients who are considered minors in the state the study is being conducted (< 18 years in most states) the parent or legal guardian should sign the consent form and the child will be required to sign a patient "assent" form, as appropriate. Patients 11-17 years of age will read and sign an Independent Review Board (IRB)-approved assent form and patients 6-10 years of age will provide verbal assent. Patients 2-5 years of age will be exempt from providing assent based on the child's comprehension and cognitive skills.
- •Clinical diagnosis of active scabies by presence of a burrow and/or typical scabietic lesions at the classic sites of infestation.
- •Parasitological confirmation of clinical diagnosis with demonstration under light microscope of mites and/or their products (larvae, eggs or fecal material).
- •Symptom score of 2 or 3 on a 4-point rating scale of 0-3 for nocturnal itching/pruritus.
- •Ability to apply or have study product applied as directed. If patient is a child, then parent/guardian will apply study product to him/her.
排除标准
- •Patients who are pregnant, lactating, or planning to become pregnant during the study.
- •Any systemic or dermatologic disorder that, in the opinion of the Investigator, will interfere with the study results or increase the risk of adverse events (AEs).
- •Known hypersensitivity to permethrin cream or any of its components.
- •Use of any systemic or topical acaricide or ectoparasiticide within one month before Screening.
- •Patient has signs of a systemic infection or is receiving systemic therapy for an infectious disease.
- •Patients with severe cutaneous bacterial or fungal infections requiring therapy (including systemic and topical antibiotics) or coexisting dermatological disorder that could interfere with the diagnosis and subsequent monitoring of scabies) or heavily crusted with lesions consistent with Norwegian scabies.
- •Patients with an underlying immunodeficient state (including prolonged treatment with corticosteroids), immunosuppressive disorders requiring therapy, severe systemic disease and history of HIV infection.
- •Any condition, medical, psychological, or social, that, in the Investigator's opinion, would interfere with participation in the study.
- •Family members of employees of the clinic or Investigator.
- •Patients who, in the opinion of the Investigator, would be non-compliant with the requirements of the study protocol.
- •Patients whose close personal contacts will not or are not willing to comply with standard of care for Scabies management.
- •Receipt of any drug as part of a research study within 30 days before Screening.
- •History of seizures.
- •Use of systemic corticosteroids within two weeks before Screening.
- •Use of topical corticosteroids within one week before Screening.
- •Previous participation in this study.
研究组 & 干预措施
Reference: Elimite™ Cream
Active Comparator
Reference: Elimite™ Cream (permethrin) 5% (Prestium Pharma, Inc.)
干预措施: Elimite™ Cream (permethrin) 5% (Drug)
Test: Permethrin Cream, 5%
Experimental
Test: Permethrin Cream, 5% (Encube Ethicals)
干预措施: Permethrin Cream, 5% (Drug)
结局指标
主要结局
Number of Patients in Each Treatment Group With Therapeutic Cure (Parasitological Cure Plus Clinical Cure) of Scabies
时间窗: Day 28 ± 4
Parasitological cure is defined as failure to demonstrate microscopically the presence of scabies infestation (i.e., no living mites, no viable mite eggs, and no mite fecal matter present). Clinical cure is defined as visual evidence of absence of new lesions and healing of original lesions, regardless the presence of post-scabietic nodules (i.e., post-scabietic nodules need not be considered as new lesions or persistence of old lesions).
次要结局
未报告次要终点
研究者
研究点 (14)
Loading locations...
相似试验
已完成
3 期
A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With ScabiesScabiesNCT03973775Saptalis Pharmaceuticals LLC126
已完成
2 期
Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested SubjectsHead LiceNCT00994422Topaz Pharmaceuticals Inc264
已完成
3 期
Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and AdultsScabiesNCT02407782University Hospital, Bordeaux1,092
已完成
2 期
A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of ScabiesScabiesNCT02094716Mylan Inc.130
已完成
3 期
A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested SubjectsHead LiceNCT01068158Topaz Pharmaceuticals Inc371